CA2208671A1 - Substituted imides as tnf inhibitors - Google Patents
Substituted imides as tnf inhibitorsInfo
- Publication number
- CA2208671A1 CA2208671A1 CA002208671A CA2208671A CA2208671A1 CA 2208671 A1 CA2208671 A1 CA 2208671A1 CA 002208671 A CA002208671 A CA 002208671A CA 2208671 A CA2208671 A CA 2208671A CA 2208671 A1 CA2208671 A1 CA 2208671A1
- Authority
- CA
- Canada
- Prior art keywords
- tnf inhibitors
- substituted imides
- inhibitors
- imides
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003949 imides Chemical class 0.000 title abstract 2
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 title 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 title 1
- GODXRDNLVMRFSG-UHFFFAOYSA-N 2-[1-(3,4-dimethoxyphenyl)propan-2-yl]isoindole-1,3-dione Chemical group C1=C(OC)C(OC)=CC=C1CC(C)N1C(=O)C2=CC=CC=C2C1=O GODXRDNLVMRFSG-UHFFFAOYSA-N 0.000 abstract 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 206010014824 Endotoxic shock Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 241001430294 unidentified retrovirus Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Novel imides of the general formula (see above formula) are inhibitors of tumor necrosis factor alpha and can be used to combat cachexia, endotoxic shock, and retrovirus replication. A typical embodiment is 2-Phthalimido-3-(3',4'-dimethoxyphenyl)propane.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/366,679 US6429221B1 (en) | 1994-12-30 | 1994-12-30 | Substituted imides |
US08/366,679 | 1994-12-30 | ||
PCT/US1995/015384 WO1996020926A1 (en) | 1994-12-30 | 1995-11-20 | Substituted imides as tnf inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2208671A1 true CA2208671A1 (en) | 1996-07-11 |
CA2208671C CA2208671C (en) | 2009-02-10 |
Family
ID=23444039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002208671A Expired - Fee Related CA2208671C (en) | 1994-12-30 | 1995-11-20 | Substituted imides as tnf inhibitors |
Country Status (20)
Country | Link |
---|---|
US (3) | US6429221B1 (en) |
EP (1) | EP0800514B1 (en) |
JP (1) | JP4118329B2 (en) |
KR (2) | KR100466838B1 (en) |
AT (1) | ATE337301T1 (en) |
AU (1) | AU709719B2 (en) |
CA (1) | CA2208671C (en) |
CZ (1) | CZ203697A3 (en) |
DE (1) | DE69535195T2 (en) |
DK (1) | DK0800514T3 (en) |
ES (1) | ES2271948T3 (en) |
FI (1) | FI972709A (en) |
HK (1) | HK1004674A1 (en) |
HU (1) | HUT77124A (en) |
NZ (1) | NZ297324A (en) |
PL (1) | PL185361B1 (en) |
PT (1) | PT800514E (en) |
RU (1) | RU2162078C2 (en) |
SK (1) | SK86897A3 (en) |
WO (1) | WO1996020926A1 (en) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5703098A (en) * | 1994-12-30 | 1997-12-30 | Celgene Corporation | Immunotherapeutic imides/amides |
US5728844A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
DE69700616T2 (en) * | 1996-07-02 | 2000-03-16 | Nisshin Flour Milling Co | Imide derivatives |
EP0918746B1 (en) * | 1996-08-12 | 2003-04-09 | Celgene Corporation | Immunotherapeutic agents and their use in the reduction of cytokine levels |
WO1998007421A1 (en) * | 1996-08-16 | 1998-02-26 | Ishihara Sangyo Kaisha, Ltd. | Medicinal composition |
EP0933360A1 (en) * | 1997-12-22 | 1999-08-04 | Pharmachemie B.V. | Synthesis of new beta-lactams |
ES2138561B1 (en) * | 1998-04-17 | 2000-07-01 | Univ Madrid Complutense | USE OF VIP PEPTIDES AND PACAP IN THE TREATMENT OF ENDOTOXIC SHOCK IN MAMMALS. |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
US6667316B1 (en) * | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US6326388B1 (en) * | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
US8030343B2 (en) | 2000-06-08 | 2011-10-04 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
EP1389203B8 (en) | 2001-02-27 | 2010-03-10 | The Governement of the United States of America, represented by The Secretary Department of Health and Human services | Analogs of thalidomide as angiogenesis inhibitors |
WO2002086078A2 (en) * | 2001-04-23 | 2002-10-31 | University Of Virginia Patent Foundation | Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic agents |
DE60235989D1 (en) | 2001-06-26 | 2010-05-27 | Amgen Fremont Inc | ANTIBODIES AGAINST OPGL |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
NZ536908A (en) * | 2002-05-17 | 2008-09-26 | Celgene Corp | Treating or preventing cancer comprising administering an effective amount of cytokine inhibitory drug plus a second active ingredient |
US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
WO2004034962A2 (en) * | 2002-10-15 | 2004-04-29 | Celgene Corporation | Selective cytokine inhibitory drugs for treating myelodysplastic syndrome |
US20040087558A1 (en) | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
US7776907B2 (en) * | 2002-10-31 | 2010-08-17 | Celgene Corporation | Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
CA2505003A1 (en) * | 2002-11-06 | 2004-05-27 | Celgene Corporation | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases |
CA2505131A1 (en) | 2002-11-06 | 2004-05-27 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
MXPA05005164A (en) * | 2002-11-18 | 2005-07-22 | Celgene Corp | Methods of using and compositions comprising (+)-3 -(3, 4-dimethoxy -phenyl)-3 -(1-oxo-1, 3-dihydro -isoindol -2-yl)- propionamide. |
US20040167199A1 (en) * | 2002-11-18 | 2004-08-26 | Celgene Corporation | Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
EP1587474B1 (en) * | 2002-12-30 | 2009-11-18 | Celgene Corporation | Fluoroalkoxy-substituted 1, 3-dihydro-isoindolyl compounds and their pharmaceutical uses |
US20040175382A1 (en) * | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
US8952895B2 (en) | 2011-06-03 | 2015-02-10 | Apple Inc. | Motion-based device operations |
SG133603A1 (en) | 2003-09-17 | 2007-07-30 | Us Gov Health & Human Serv | Thalidomide analogs as tnf-alpha modulators |
US20050142104A1 (en) * | 2003-11-06 | 2005-06-30 | Zeldis Jerome B. | Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders |
EP1692128A1 (en) | 2003-11-19 | 2006-08-23 | Signal Pharmaceuticals LLC | Indazole compounds and methods of use thereof as protein kinase inhibitors |
US7684506B2 (en) | 2004-02-13 | 2010-03-23 | Panasonic Corporation | Transmitter apparatus, receiver apparatus, and wireless communication method |
BRPI0418743A (en) * | 2004-04-14 | 2007-09-18 | Celgene Corp | methods of treating, preventing or controlling a myelodysplastic syndrome, reducing or preventing an adverse effect associated with the administration of a second active ingredient in a patient suffering from a myelodysplastic syndrome, pharmaceutical composition, single unit dosage form, and kit |
WO2005102317A1 (en) * | 2004-04-23 | 2005-11-03 | Celgene Corporation | Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension |
US20070190070A1 (en) * | 2004-09-03 | 2007-08-16 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
WO2006028963A2 (en) | 2004-09-03 | 2006-03-16 | Celgene Corporation | Substituted heterocyclic compounds and uses thereof |
JP2008518924A (en) * | 2004-10-28 | 2008-06-05 | セルジーン・コーポレーション | Methods and compositions using PDE4 modulators for treatment and management of central nervous system injury |
US20080138295A1 (en) * | 2005-09-12 | 2008-06-12 | Celgene Coporation | Bechet's disease using cyclopropyl-N-carboxamide |
CN102387798A (en) | 2009-02-10 | 2012-03-21 | 细胞基因公司 | Methods of using and compositions comprising PDE4 modulators for treatment, prevention and management of tuberculosis |
US9408831B2 (en) | 2010-04-07 | 2016-08-09 | Celgene Corporation | Methods for treating respiratory viral infection |
AU2011268450B2 (en) | 2010-06-15 | 2015-07-16 | Amgen (Europe) GmbH | Biomarkers for the treatment of psoriasis |
US8927725B2 (en) | 2011-12-02 | 2015-01-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thio compounds |
US20170087129A1 (en) | 2014-05-16 | 2017-03-30 | Celgene Corporation | Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators |
WO2017070291A1 (en) | 2015-10-21 | 2017-04-27 | Celgene Corporation | Pde4 modulators for treating and preventing immune reconstitution inflammatory syndrome (iris) |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) * | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4215114A (en) * | 1976-11-12 | 1980-07-29 | The Upjohn Company | Analgesic N-[2-(furyl-methylamino and 2-thienylmethylamino)cycloaliphatic]be |
IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5073543A (en) * | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (en) * | 1989-03-22 | 1991-07-25 | Bioresearch Spa | USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS. |
US5120548A (en) * | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
KR0166088B1 (en) * | 1990-01-23 | 1999-01-15 | . | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
US5733566A (en) * | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
JPH0625163A (en) * | 1992-07-03 | 1994-02-01 | Ube Ind Ltd | N-@(3754/24)dimethoxybenzyl)phthalimide compounds and their production |
AU5165093A (en) * | 1992-10-08 | 1994-05-09 | E.I. Du Pont De Nemours And Company | Fungicidal and miticidal aminopyrimidines |
US5591767A (en) * | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US5541213A (en) * | 1993-06-24 | 1996-07-30 | Eisai Co., Ltd. | Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility |
US5463063A (en) | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
US5605914A (en) * | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
RU2139281C1 (en) * | 1993-11-30 | 1999-10-10 | Джи Ди Сирл энд Компани | Pyrazolyl-substituted benzenesulfoneamide or its pharmaceutically acceptable salt, method of treatment of patients with inflammation or inflammation-associated diseases |
IT1270594B (en) * | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN |
US5801195A (en) * | 1994-12-30 | 1998-09-01 | Celgene Corporation | Immunotherapeutic aryl amides |
US5703098A (en) * | 1994-12-30 | 1997-12-30 | Celgene Corporation | Immunotherapeutic imides/amides |
US5703092A (en) * | 1995-04-18 | 1997-12-30 | The Dupont Merck Pharmaceutical Company | Hydroxamic acid compounds as metalloprotease and TNF inhibitors |
US5728844A (en) | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
US5728845A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic nitriles |
US5658940A (en) * | 1995-10-06 | 1997-08-19 | Celgene Corporation | Succinimide and maleimide cytokine inhibitors |
US5798368A (en) * | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
ES2529190T3 (en) | 1996-07-24 | 2015-02-17 | Celgene Corporation | 2- (2,6-Dioxopiperidin-3-yl) -amino-substituted phthalimides to reduce TNF-alpha levels |
HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
EP0918746B1 (en) * | 1996-08-12 | 2003-04-09 | Celgene Corporation | Immunotherapeutic agents and their use in the reduction of cytokine levels |
RU2199530C2 (en) * | 1997-07-31 | 2003-02-27 | Селджин Корпорейшн | SUBSTITUTED HYDROXAMIC ACIDS, PHARMACEUTICAL COMPOSITIONS BASED ON THEREOF AND METHOD OF TNF (TUMOR NECROSIS FACTOR) α DECREASE |
US5955476A (en) * | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
US5874448A (en) * | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
SE9803710L (en) | 1998-09-25 | 2000-03-26 | A & Science Invest Ab | Use of certain substances for the treatment of nerve root damage |
US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
CN1342146A (en) * | 1999-03-18 | 2002-03-27 | 塞尔基因公司 | Substituted 1-oxo-and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels |
US6667316B1 (en) | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US6326388B1 (en) * | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
US6699899B1 (en) | 1999-12-21 | 2004-03-02 | Celgene Corporation | Substituted acylhydroxamic acids and method of reducing TNFα levels |
US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
-
1994
- 1994-12-30 US US08/366,679 patent/US6429221B1/en not_active Expired - Fee Related
-
1995
- 1995-11-20 CZ CZ972036A patent/CZ203697A3/en unknown
- 1995-11-20 PT PT95940847T patent/PT800514E/en unknown
- 1995-11-20 CA CA002208671A patent/CA2208671C/en not_active Expired - Fee Related
- 1995-11-20 KR KR1019970704510A patent/KR100466838B1/en not_active IP Right Cessation
- 1995-11-20 WO PCT/US1995/015384 patent/WO1996020926A1/en active IP Right Grant
- 1995-11-20 EP EP95940847A patent/EP0800514B1/en not_active Expired - Lifetime
- 1995-11-20 HU HU9701849A patent/HUT77124A/en unknown
- 1995-11-20 NZ NZ297324A patent/NZ297324A/en not_active IP Right Cessation
- 1995-11-20 AT AT95940847T patent/ATE337301T1/en not_active IP Right Cessation
- 1995-11-20 ES ES95940847T patent/ES2271948T3/en not_active Expired - Lifetime
- 1995-11-20 AU AU42463/96A patent/AU709719B2/en not_active Ceased
- 1995-11-20 KR KR10-2003-7016455A patent/KR20040007729A/en not_active Application Discontinuation
- 1995-11-20 SK SK868-97A patent/SK86897A3/en unknown
- 1995-11-20 PL PL95321065A patent/PL185361B1/en not_active IP Right Cessation
- 1995-11-20 DK DK95940847T patent/DK0800514T3/en active
- 1995-11-20 JP JP52098696A patent/JP4118329B2/en not_active Expired - Fee Related
- 1995-11-20 RU RU97112858/04A patent/RU2162078C2/en not_active IP Right Cessation
- 1995-11-20 DE DE69535195T patent/DE69535195T2/en not_active Expired - Lifetime
-
1997
- 1997-06-23 FI FI972709A patent/FI972709A/en unknown
-
1998
- 1998-02-17 HK HK98101231A patent/HK1004674A1/en not_active IP Right Cessation
-
2002
- 2002-03-25 US US10/105,833 patent/US6844359B2/en not_active Expired - Fee Related
-
2004
- 2004-11-16 US US10/989,945 patent/US7329761B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP4118329B2 (en) | 2008-07-16 |
PL185361B1 (en) | 2003-04-30 |
RU2162078C2 (en) | 2001-01-20 |
HUT77124A (en) | 1998-03-02 |
KR20040007729A (en) | 2004-01-24 |
DE69535195D1 (en) | 2006-10-05 |
US20050090516A1 (en) | 2005-04-28 |
KR980700968A (en) | 1998-04-30 |
US6429221B1 (en) | 2002-08-06 |
HK1004674A1 (en) | 1998-12-04 |
ES2271948T3 (en) | 2007-04-16 |
FI972709A (en) | 1997-08-29 |
US6844359B2 (en) | 2005-01-18 |
FI972709A0 (en) | 1997-06-23 |
US7329761B2 (en) | 2008-02-12 |
SK86897A3 (en) | 1998-01-14 |
KR100466838B1 (en) | 2005-09-02 |
CZ203697A3 (en) | 1997-11-12 |
AU709719B2 (en) | 1999-09-02 |
PL321065A1 (en) | 1997-11-24 |
NZ297324A (en) | 2000-03-27 |
PT800514E (en) | 2006-12-29 |
EP0800514A1 (en) | 1997-10-15 |
US20020143027A1 (en) | 2002-10-03 |
WO1996020926A1 (en) | 1996-07-11 |
CA2208671C (en) | 2009-02-10 |
AU4246396A (en) | 1996-07-24 |
DE69535195T2 (en) | 2007-07-12 |
DK0800514T3 (en) | 2006-12-27 |
ATE337301T1 (en) | 2006-09-15 |
JPH10511946A (en) | 1998-11-17 |
EP0800514B1 (en) | 2006-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2208671A1 (en) | Substituted imides as tnf inhibitors | |
DE69522961D1 (en) | Immunotherapeutische arylamide | |
EP1367051A3 (en) | Inhibitors of tumor necrosis factor alpha | |
CA2233975A1 (en) | Succinimide and maleimide cytokine inhibitors | |
EP1004572A3 (en) | Amines as inhibitors of TNF alpha | |
AU3781397A (en) | Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf) | |
AU1937397A (en) | Substituted indazole derivatives and their use as inhibitors phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf) | |
CA2262906A1 (en) | Novel immunotherapeutic agents and their use in the reduction of cytokine levels | |
AU2785797A (en) | Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors | |
AU664046B2 (en) | Polypeptide inhibitor of the replication of HSU and similar viruses | |
CA2104214A1 (en) | Cytokine inhibitors | |
CA2208672A1 (en) | Immunotherapeutic imides/amides and their use for reducing levels of tnf.alpha. | |
CA2270423A1 (en) | Prophylactic/therapeutic agent | |
GB8926611D0 (en) | Compound and its use | |
ZA918116B (en) | Inhibitors for the formation of tumor necrosis factor,processes for the preparation thereof and the use thereof | |
CA2176962A1 (en) | N-substituted azabicycloheptane derivatives, their preparation and use | |
RU96106043A (en) | MIXTURE FOR MANUFACTURE OF SEEDING POTS OR BRIQUETTES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |